Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer
- 1 June 1981
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 1 (2), 125-130
- https://doi.org/10.1007/bf01805865
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routesCancer Chemotherapy and Pharmacology, 1980
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- A radioimmunoassay for serum medroxyprogesterone acetateThe Journal of Steroid Biochemistry and Molecular Biology, 1978
- High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response EvaluationTumori Journal, 1978
- High Dose Medroxyprogesterone-Acetate Treatment in Advanced Mammary Carcinoma: A Phase II InvestigationActa Radiologica: Oncology, Radiation, Physics, Biology, 1978
- [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].1977
- Serum Medroxyprogesterone Acetate (MPA) Concentrations and Ovarian Function Following Intramuscular Injection of Depo-MPAJournal of Clinical Endocrinology & Metabolism, 1977
- Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of depo-provera® to womenContraception, 1976
- Epithioandrostanol (10275-S), an Estrogen AntagonistEndocrinologia Japonica, 1973
- Measurement of Medroxyprogesterone Acetate (Provera) by Radioimmunoassay1Journal of Clinical Endocrinology & Metabolism, 1971